Back to search

Finland· FI-REL-REL5033

Cardiorytmin Retard

A procainamide product, registered in Finland by Schering Oy. The same ATC class is registered in 5 of our 19 countries.

ATC C01BA02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedCardiorytmin RetardATCC01BA02REGISTER NO.FI-REL-REL5033PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Procainamide is registered in 5 of 19 countries.

Countries holding a registration under ATC C01BA02 (procainamide), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 2 of them publish a price we can compare per daily dose

Procainamide · ATC C01BA02

5 / 19 countries

  • Canada
  • Finlandprice
  • Japan
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Manufacturer
Schering Oy
Country
Finland (FI)
ATC code
C01BA02
ATC class
Procainamide
Defined daily dose
3 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

236 interactions on record for procainamide.

Graded by severity as the source publishes them — 138 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Procainamide · interactions on record

236 records

  • 138 severe
  • 85 moderate
  • 8 minor
  • 4 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/48f0b35e-3938-4df7-baa3-87b2dd3cb37b
GET /v1/drugs/48f0b35e-3938-4df7-baa3-87b2dd3cb37b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "3",
  "form": "depottabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "400 mg",
  "atc_label": "prokaiiniamidi",
  "ma_number": "6391",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL5033",
  "authorised_at": "1972-05-10"
}

See everything about procainamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.